Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: A 6-month double-blind study

International Journal of Clinical Pharmacology Research

Volumn 21, Issue 1, 2001, Pages 43-57

  Castano G ^a   Mas, R ^a   Fernandez L ^a   Illnait, J ^a   Gamez R ^a   Alvarez, E ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALKANOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0034775530     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Cardiovascular disease epidemiology. A journey from the past into the future
2. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
3. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
4. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention
5. European and American recommendations for coronary heart disease prevention
6. An updated coronary risk profile. A statement for health professionals
7. The lipid research clinics coronary primary prevention trial results I. Reduction in the incidence of coronary heart disease
8. The lipid research clinics coronary primary prevention trial results II. The relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering
9. Helsinki Heart Study: Primary-prevention with gemfibrozil in middle-aged men with dyslipidemia
10. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease, the Scandinavian Simvastatin Survival Study (4S)
11. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
12. Long-term intervention with pravastatin in ischemic disease (LIPID) study. Clinical implications for cardiovascular practice
13. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
14. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
15. Combination of drug therapy for hypercholesterolemia, the trade-off between cost and simplicity
16. Drug therapy for hypercholesterolemia in patients with cardiovascular disease, factors limiting achievement of lipid goals
17. LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European atherosclerosis society lipid goals
18. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidemia
19. Reduction of LDL-C by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMGCoA reductase inhibitor
20. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The Curves Study)
21. Cost of treating to a modified European Atheroesclerosis Society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin
22. Efficacy and six-month safety of simvastatin 80 mg/day. Results from the Worldwide Simvastatin Expanded dose program (WSEDP)
23. Policosanol
24. Estudio dosis-efecto de la acción hipocolesterolémica del policosanol en pacientes con hiperlipoproteinemia tipo II
25. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment
26. Effects of successive dose increases of policosanol on the lipid profile and tolerability of treatment
27. Efficacy and safety of policosanol in patients with primary hypercholesterolemia
28. One year efficacy and safety of policosanol in patients with type II hyperholesterolemia
29. Effect of policosanol in lowering-cholesterol levels in patients with type II hypercholesterolemia
30. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia
31. One year study on the effect of policosanol (5 mg-twice-a-day) on lipid profile in patients with type II hypercholesterolemia
32. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia, a 12 months study
33. A two year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinemia
34. Effects of policosanol in hypertensive patients with type II hypercholesterolemia
35. Effects of policosanol on hypercholesterolemic patients with disturbances on serum biochemical indicators of hepatic function
36. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia
37. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia
38. Effects of policosanol on primary hypercholesterolemia, A 3-year open follow-up
39. Open-label study of the efficacy, safety and tolerability of policosanol in patients with high coronary risk
40. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
41. A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk
42. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients
43. Efficacy and tolerability of policosanol compared with lovastatin in patients with Type II hypercholesterolemia and concomitant risk factors
44. Effect of policosanol on postmenopausal women with type II hypercholesterolemia
45. Effect of policosanol in older patients with type II hypercholesterolemia and high coronary risk
46. Treatment of hypercholesterolemia in NIDDM with policosanol
47. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: A pilot study
48. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus
49. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without of the preparative ultracentrifuge
50. Separation of serum high-density lipoprotein for cholesterol determination, ultracentrifugation vs. precipitation with sodium phosphotungstat and magnesium chloride
51. Statistical considerations for performing multiple tests in a single experiment 5. Comparing two therapies with respect to several endpoints
52. Pharmacoepidemiologic study of policosanol
53. Policosanol, results of a postmarketing surveillance control on 27,879 cases